| Title |
Efficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-Analysis
|
|---|---|
| Published in |
PLOS ONE, August 2012
|
| DOI | 10.1371/journal.pone.0041870 |
| Pubmed ID | |
| Authors |
Konstantinos A. Polyzos, Michael N. Mavros, Konstantinos Z. Vardakas, Marinos C. Makris, Petros I. Rafailidis, Matthew E. Falagas |
| Abstract |
The epidemiology and antibiotic resistance of Staphylococcus aureus have evolved, underscoring the need for novel antibiotics, particularly against methicillin-resistant S. aureus (MRSA). Telavancin is a bactericidal lipoglycopeptide with potent activity against Gram-positive pathogens. |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 47 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 15% |
| Other | 5 | 11% |
| Student > Ph. D. Student | 4 | 9% |
| Researcher | 4 | 9% |
| Student > Doctoral Student | 3 | 6% |
| Other | 12 | 26% |
| Unknown | 12 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 32% |
| Biochemistry, Genetics and Molecular Biology | 5 | 11% |
| Agricultural and Biological Sciences | 3 | 6% |
| Immunology and Microbiology | 3 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 16 | 34% |